{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"groups":[{"description":"lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.\n\ndexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.\n\nlenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone","id":"OG000","title":"Revlimid"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Patients Who Received Both CC-5013 and Dexamethasone and Had a Hematologic Response","type":"SECONDARY","unitOfMeasure":"participants"}